Table 3.
Treatment | Total females caught | Total blood-fed | % blood-feeding* | 95% CIs | % blood-feeding inhibition | % personal protection |
---|---|---|---|---|---|---|
Trial 1 | ||||||
Untreated net | 664 | 481 | 72a | 69–76 | – | – |
Olyset plus | 511 | 122 | 24b | 20–28 | 67 | 75 |
Bendiocarb IRS | 556 | 528 | 95c | 93–97 | − 31 | − 10 |
Olyset Plus + bendiocarb IRS | 288 | 64 | 22b | 17–27 | 69 | 87 |
P-methyl IRS | 531 | 420 | 79d | 76–83 | − 9 | 13 |
Olyset Plus + P-methyl IRS | 304 | 47 | 16e | 11–20 | 79 | 90 |
Trial 2 | ||||||
Untreated net | 581 | 391 | 67u | 64–71 | – | – |
PermaNet 3.0 | 488 | 115 | 24v | 20–27 | 65 | 71 |
Bendiocarb IRS | 575 | 519 | 90w | 88–93 | − 34 | − 33 |
PermaNet 3.0 + bendiocarb IRS | 233 | 54 | 23v | 18–29 | 66 | 86 |
P-methyl IRS | 450 | 406 | 90w | 88–93 | − 34 | − 4 |
PermaNet 3.0 + P-methyl IRS | 223 | 55 | 25v | 19–30 | 63 | 86 |
Results are presented separately for the trials involving Olyset Plus (Trial 1) and PermaNet 3.0 (Trial 2).
*For each trial, values on this column sharing a superscript letter do not differ significantly, P > 0.05, logistic regression.